Results 141 to 150 of about 32,298 (248)

Societal preferences for funding orphan drugs in China: An application of the discrete choice experiment method. [PDF]

Front Public Health, 2022
Tan S, Wang Y, Tang Y, Jiang R, Chen M, Chen H, Yang F.   +6 more
europepmc   +1 more source

Narcolepsy and rapid eye movement sleep

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, Yves Dauvilliers   +4 more
wiley   +1 more source

Establishment of a value assessment framework for orphan drugs in China: an application of the discrete choice experiment in multicriteria decision analysis. [PDF]

Front Pharmacol
Zhao Z, Tang X, Hu M.
europepmc   +1 more source

Criteria to define rare diseases and orphan drugs: a systematic review protocol. [PDF]

BMJ Open, 2022
Abozaid GM, Kerr K, McKnight A, Al-Omar HA.   +3 more
europepmc   +1 more source

Diagnostic Value of Psychomotor Vigilance Task for Severe Sleep Inertia in Idiopathic Hypersomnia Versus Other Sleep Disorders Without Sleep Inertia

Journal of Sleep Research, EarlyView.
Diagnostic Value of PVT for Severe Sleep Inertia in Idiopathic Hypersomnia. ABSTRACT Sleep inertia impairs performance upon awakening and may be assessed using the psychomotor vigilance task (PVT). This study aimed to determine optimal PVT lapse cut‐offs at awakening to objectively measure sleep inertia by comparing patients with idiopathic hypersomnia
Elisa Evangelista, Alexandre Derré, Lucie Barateau, Anna Laura Rassu, Sofiene Chenini, Isabelle Jaussent, Yves Dauvilliers   +6 more
wiley   +1 more source

New opportunities for accessing promising non-oncological orphan drugs. [PDF]

Lancet Reg Health Eur
Hollak CEM, Reparon-Schuijt CC, Verdeyen K, Deesker LJ, Groothoff JW, Vos JMI, Huisman AH, van der Flier S, Pisters-van Roy AAMG.   +8 more
europepmc   +1 more source

Postmortem Evidence of CRH Neuron Reduction in Narcolepsy Without Cataplexy With Borderline Hypocretin‐1 Levels

Journal of Sleep Research, EarlyView.
ABSTRACT Narcolepsy is classified as type 1 (NT1) or type 2 (NT2) mainly according to hypocretin deficiency rather than cataplexy. While CRH neuron loss in the PVN has been described in NT1, it remains unclear whether similar changes occur in narcolepsy without cataplexy.
Ling Shan, Suzan Linssen, Rolf Fronczek, Lucie Barateau, Christelle Peyron, Yves Dauvilliers   +5 more
wiley   +1 more source

The clinical assessment of studies on orphan drugs in relation to the EMA's authorization marketing decisions in Europe. [PDF]

Front Pharmacol
Jakubowski S, Malinowski KP, Kawalec P.
europepmc   +1 more source

Orphan Drugs, Compounded Medication and Pharmaceutical Commons. [PDF]

Front Pharmacol, 2021
Hendrickx K, Dooms M.
europepmc   +1 more source

Betwixt playing the waiting game and waiting in vain: Temporal governance and the thin alignment of care under universal health coverage in Kenya

Medical Anthropology Quarterly, EarlyView.
Abstract This article investigates how Kenyan citizens access healthcare within the framework of Universal Health Coverage (UHC) reforms. Based on ethnographic fieldwork, it reconceptualizes waiting as a politically structured phenomenon rather than a simple delay. The analysis shows that UHC reforms do not eliminate waiting but instead redistribute it,
Edwin Ambani Ameso
wiley   +1 more source